Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
32 participants
INTERVENTIONAL
2013-03-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of NeuroAD on the Cognitive Function of Alzheimer Patients
NCT01825330
tDCS and Cognitive Training for Mild Cognitive Impairment and Alzheimer's Dementia
NCT04507815
Enhancing Neuroplasticity and Frontal Lobe Function in Patients With Mild Alzheimer's Disease
NCT01847586
TMS Stimulation and Cognitive Training in Alzheimer Patients
NCT01168245
Combined tDCS and Cognitive Training in Alzheimer's
NCT06861231
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Evaluation is by neuropsychological evaluation at 6 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NeuroAD
Treatment by the NeuroAD device, real treatment by synchronized TMS+cognitive training
NeuroAD
synchronized TMS+COGNITIVE TRAINING
Sham NeuroAD
Sham TMS+cog, has the same sound and appearance, patients come for the same number of treatments and are exposed to the same procedure.
Sham device
Sham TMS+cog, has the same sound and appearance as the real device, delivers no energy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NeuroAD
synchronized TMS+COGNITIVE TRAINING
Sham device
Sham TMS+cog, has the same sound and appearance as the real device, delivers no energy.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients diagnosed with mild or moderate stage of Alzheimer's Disease, according to the DSM-IV criteria.
3. MMSE score 18 to 26
4. Adas-cog above 17
5. Physically acceptable for the study as confirmed by medical history and exam.
6. Spouse, family member or professional caregiver agree and capable of taking care and be responsible for the participation of the patient in the study (answering questions regarding the patient's condition and assuming responsibility for medication)
7. Agreement to participate in approximately 14 weeks during the study.
8. Normal or corrected to normal ability to see and to hear.
9. Korean as primary language
10. 8th grade education minimum
Exclusion Criteria
2. Severe agitation;
3. Mental retardation;
4. Patient lacking capacity to consent to study participation
5. Unstable medical condition;
6. Use of benzodiazepines or barbiturates during the study and preceding two weeks;
7. Pharmacological immunosuppression;
8. Participation in a clinical trial with any investigational agent within two weeks prior to study enrollment;
9. History of Epileptic Seizures or Epilepsy;
10. Contraindication for performing MRI scanning;
11. Contraindication for receiving TMS treatment according to a TMS questionnaire;
12. Pregnant women, and women who have the ability to become pregnant unless they are on an acceptable method of contraception during the study.
13. Patients with personal history of any clinically defined neurological disorder, including organic brain disease, epilepsy, stroke, brain lesions, or multiple sclerosis; or personal history of previous neurosurgery or head trauma that resulted in loss of consciousness.
14. Patients with depression, bipolar disorder or psychotic disorders or any other neurological or psychiatric condition (whether now or in the past), which the Investigator finds as interfering with the study
15. Alcoholism or drug addiction as defined by DSM-IV within last 5 years (addicted more than one year and or in remission less than 3 years) or severe sleep deprivation
16. Patients treated with cholinesterase inhibitors, or memantine or Ginko-biloba will be allowed to participate, if the treatment has started at least 6 months previous to recruitment. The patients should keep their dose of medication during the whole trial as prior to study begin.
17. Patients with metal in the head, except the mouth (i.e. cochlear implants, implanted brain stimulators, aneurysm clips)
18. Patients with increased intracranial pressure
19. Cardiac pacemakers
20. Implanted neurostimulators
21. Implanted medication pumps
22. Intracardiac lines
23. Significant heart disease
24. Currently taking medication that lower the seizure threshold
25. Significant sleep deprivation and alcoholism
60 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
company: K The Power
UNKNOWN
Chungnam National University Hospital
OTHER
Neuronix Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chungnam national university hospital, Daejeon Geriatric Medical Center
Daejeon, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NRX-KOR1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.